Markets:

News

Articles published by Exai Bio

Exai Bio Appoints Oncology Leader and Former American Cancer Society CEO, Karen E. Knudsen, MBA, PhD, to its Board of Directors

December 05, 2024

From Exai Bio

Via Business Wire

Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform

November 21, 2024

From Exai Bio

Via Business Wire

Exai Bio Appoints Dave Daly as Chief Executive Officer

July 24, 2024

From Exai Bio

Via Business Wire

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

April 08, 2024

From Exai Bio

Via Business Wire

Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches

December 06, 2023

From Exai Bio

Via Business Wire

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

September 12, 2023

From Exai Bio

Via Business Wire

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

June 03, 2023

From Exai Bio

Via Business Wire

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting

April 18, 2023

From Exai Bio

Via Business Wire

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

March 30, 2023

From Exai Bio

Via Business Wire

Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team

February 02, 2023

From Exai Bio

Via Business Wire

Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages

December 06, 2022

From Exai Bio

Via Business Wire

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

September 10, 2022

From Exai Bio

Via Business Wire

Exai Bio Demonstrates Its Unique RNA-based Liquid Biopsy Strategy for Early Detection and Monitoring of Multiple Cancers

April 12, 2022

From Exai Bio

Via Business Wire

Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection

December 09, 2021

From Exai Bio

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.